Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
Beijing, CN
Beijing Konruns Pharmaceutical Co.,Ltd., a Chinese company established in 2003 and based in Beijing, focuses on the discovery, production, and distribution of various pharmaceutical items. Among its key offerings is Su Ling, a hemagglutinin preparation designed to minimize blood loss during surgical procedures and manage post-operative bleeding. The firm is also actively developing a pipeline of potential new medicines, such as CX1026, CX1003, and KC1036.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.57% | -9.34% | -2.68% | -19.73% | -22.90% | -13.33% | +11.02% | -8.98% | -6.13% | -1.71% | -1.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+10.9% ★ Q1'26: +1.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+285.2% ★ Q1'26: +7.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+7.6% Q1'26: +5.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+21.6% ★ Q1'26: +28.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+5.9% ★ Q1'26: +6.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.1% ★ Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.33× ★ Q1'26: 1.32× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
920.01M
est: 937.00M (-1.8%)
|
825.40M
est: 868.50M (-5.0%)
|
915.12M
est: 1.03B (-11.2%)
|
1.08B
1.08B – 1.08B
+4.4% YoY
|
1.23B
1.23B – 1.23B
+14.5% YoY
|
1.54B
1.54B – 1.54B
+24.7% YoY
|
| EBITDA |
165.35M
est: 165.99M (-0.4%)
|
146.73M
est: 167.73M (-12.5%)
|
233.49M
est: 198.93M (+17.4%)
|
207.62M
207.62M – 207.62M
+4.4% YoY
|
237.74M
237.74M – 237.74M
+14.5% YoY
|
296.46M
296.46M – 296.46M
+24.7% YoY
|
| EBIT |
129.54M
est: 131.11M (-1.2%)
|
118.77M
est: 134.97M (-12.0%)
|
197.22M
est: 160.07M (+23.2%)
|
167.06M
167.06M – 167.06M
+4.4% YoY
|
191.31M
191.31M – 191.31M
+14.5% YoY
|
238.55M
238.55M – 238.55M
+24.7% YoY
|
| Net Income |
150.45M
est: 157.92M (-4.7%)
|
42.22M
est: 44.68M (-5.5%)
|
165.97M
est: 159.58M (+4.0%)
|
187.78M
186.25M – 189.30M
+17.7% YoY
|
214.91M
214.91M – 214.91M
+14.4% YoY
|
272.89M
272.89M – 272.89M
+27.0% YoY
|
| SGA |
583.28M
est: 593.27M (-1.7%)
|
553.76M
est: 496.95M (+11.4%)
|
327.05M
est: 589.36M (-44.5%)
|
615.11M
615.11M – 615.11M
+4.4% YoY
|
704.37M
704.37M – 704.37M
+14.5% YoY
|
878.31M
878.31M – 878.31M
+24.7% YoY
|
| EPS |
0.96
est: 1.01 (-5.0%)
|
0.27
est: 0.28 (-3.6%)
|
1.05
est: 1.00 (+5.0%)
|
1.18
1.17 – 1.19
+17.7% YoY
|
1.35
1.35 – 1.35
+14.4% YoY
|
1.71
1.71 – 1.71
+27.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 54.2K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jing Wang | Accounting Supervisor | — | — |
| Xiao Dong Huang | Secretary to the Board | — | — |
| Xiaohan Liu | Chief Financial Officer & Director | — | male |
| Zhanqi Niu | President & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603590.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
